Comorbidity of opioid-related and anxiety-related symptoms and disorders
- PMID: 30711906
- PMCID: PMC6609499
- DOI: 10.1016/j.copsyc.2018.12.020
Comorbidity of opioid-related and anxiety-related symptoms and disorders
Abstract
Opioid use disorder and anxiety disorders co-occur at strikingly high rates, and this comorbidity is marked by a more severe clinical presentation and poorer prognosis for treatment. Given the substantial morbidity and mortality associated with these two disorders, it is imperative to understand factors related to the high rates of co-occurrence in order to inform the development of specialized treatments for this population. Several lines of study suggest that simultaneously addressing opioid-related and anxiety-related symptoms and processes, particularly intolerance of distress and pain-related anxiety, may yield improved outcomes for this high risk, vulnerable population. Future work is needed to identify other novel mechanisms as well as develop specialized treatments to augment standard medication-assisted treatment.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Conflict of interest statement
References
-
- Centers for Disease Control: Increases in drug and opioid overdose deaths—United States, 2000–2014. Morbidity and Mortality Weekly Report 2016, 64:1378–82. - PubMed
-
- Substance Abuse and Mental Health Services Administration: National Survey on Drug Use and Health 2016.
-
- Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL: Societal costs of prescription opioid abuse, dependence and misuse in the United States. Pain Med 2011, 12: 657–667. - PubMed
-
- Jones CM, Mack K A, Paulozzi LJ: Pharmaceutical overdose deaths, United States. JAMA 2013, 309: 657–659. - PubMed
-
- National Institute of Mental Health: Anxiety Disorders. 2018.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
